RNA, U1 small nuclear 89, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-89P profile across patient tissues and cancer cell-line models. RNU1-89P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU1-89P is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, RNU1-89P RNA expression shows 9,173 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight BLCA, KIRC, and BRCA as cancer lineages where RNU1-89P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-89P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-89P survival associations across molecular data types. RNU1-89P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-89P RNA expression–survival associations across cancer types. High RNU1-89P expression shows unfavorable associations in BLCA, LGG, PRAD, UCEC and ACC, but favorable associations in HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU1-89P RNA expression.
This table summarizes RNU1-89P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-89P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-89P shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in BRCA and LUAD. The KIRC box plot shows higher RNU1-89P RNA expression in normal versus tumor tissue (log2 FC = −0.184, t-test p < 0.001).
This table shows molecular features associated with RNU1-89P in patient tissues and cancer cell lines. In patient samples, RNU1-89P shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
